$3.92
8.41% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
US7133171055
Symbol
PEPG
Sector
Industry

PepGen Stock price

$3.92
-1.18 23.14% 1M
-12.54 76.18% 6M
-2.88 42.35% YTD
-3.19 44.87% 1Y
-8.97 69.59% 3Y
-8.97 69.59% 5Y
-8.97 69.59% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.36 8.41%
ISIN
US7133171055
Symbol
PEPG
Sector
Industry

Key metrics

Market capitalization $127.78m
Enterprise Value $7.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.93
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-94.21m
Free Cash Flow (TTM) Free Cash Flow $-82.77m
Cash position $138.86m
EPS (TTM) EPS $-2.98
P/E forward negative
Short interest 4.72%
Show more

Is PepGen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

PepGen Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a PepGen forecast:

4x Buy
80%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a PepGen forecast:

Buy
80%
Sell
20%

Financial data from PepGen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.48 1.48
51% 51%
-
-1.48 -1.48
51% 51%
-
- Selling and Administrative Expenses 19 19
24% 24%
-
- Research and Development Expense 72 72
13% 13%
-
-93 -93
16% 16%
-
- Depreciation and Amortization 1.48 1.48
51% 51%
-
EBIT (Operating Income) EBIT -94 -94
16% 16%
-
Net Profit -87 -87
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about PepGen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PepGen Stock News

Neutral
Business Wire
13 days ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Dru...
Neutral
Business Wire
about one month ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen's 2024 Inducement Plan as a material inducement to employment to its newly appointed Senior...
Neutral
Business Wire
about 2 months ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2024. “We are pleased with the progress we have ma...
More PepGen News

Company Profile

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Head office United States
CEO James McArthur
Employees 64
Founded 2018
Website pepgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today